A thought-provoking idea would be to combine this type of novel anti-obesity agents with CA VA/VB inhibitors, either as a combination therapy or by including CA inhibitory moieties in the oligopeptide structure, in order to obtain hybrids with dual action on GLP-1 as well as the two mitochondrial CA enzymes. Here, GCG is linked to Obesity.